LONDON, February 26 /PRNewswire/ -- Expert Opinion provides systematic and authoritative analysis enabling the pharmaceutical community to access and track key developments that lead to the creation of new drugs. Expert Opinion on Pharmacotherapy, Expert Opinion on Biological Therapy and Expert Opinion on Therapeutic Targets are now accepting original research.
Why publish with Expert Opinion
All the Expert Opinion journals publish independent and authoritative peer-reviewed articles; provide efficient and effective editorial support through from submission to publication that can take as little as 8 - 12 weeks. The journals are indexed by all major databases, including: Medline, Current Contents and EMBASE.
About the journals
Expert Opinion on Pharmacotherapy provides comprehensive coverage of emerging literature on newly approved compounds and assesses the likely impact of these new agents on existing pharmacotherapy of specific diseases. Expert Opinion on Pharmacotherapy focuses on new drugs and classes from development Phase III to those that have been available to pharmacopoeia for up to five years. Impact Factor: 1.733
Expert Opinion on Biological Therapy covers all aspects of biological therapy, from therapeutic peptides and proteins to gene transfer technologies and drug delivery systems, placing new advances in the context of current therapeutic practice and providing an expert opinion on the scope for future development. Impact Factor: 2.705
Expert Opinion on Therapeutic Targets publishes in-depth reports and
reviews of the latest developments in the field of drug target discovery
and validation. The journal provides an essential link between basic
research on biological pathways and interactions and the development of the
drugs for tomorrow. It is distinguished from other publications by its
high-quality authorship and expertly drafted articles, structured to
incorporate the author's expertise on the subject. Impact Factor: 2.662
For more information, please contact:
Tel no: +44(0)20-7017-4742
|SOURCE Expert Opinion|
Copyright©2008 PR Newswire.
All rights reserved